Company Filing History:
Years Active: 1993-1995
Title: Innovator Takeshi Doi: Pioneering Advances in Protein Receptors
Introduction
Takeshi Doi, an accomplished inventor based in Kodaira, Japan, has made significant contributions to the field of biopharmaceuticals. His work primarily revolves around recombinant proteins and their applications in medical research and therapy. With a total of two patents to his name, Doi's innovations are paving the way for advancements in the treatment of various diseases.
Latest Patents
Doi's latest patents focus on recombinant protein receptors for interleukin-2 (IL-2). The first patent pertains to the recombinant IL-21R.beta. chain, including fragments, along with the cDNA coding for the protein. This invention also encompasses vectors that contain the cDNA, hosts that are transfected by these vectors, and monoclonal antibodies targeted at the recombinant IL-2R.beta.
In the second patent, Doi explores the recombinant IL-2R.mu. protein and its fragments. Similar to the first, this invention includes the cDNA coding for the IL-2R.mu. protein, various vectors, and hosts that are transfected with the associated vectors, as well as monoclonal antibodies to the encoded recombinant IL-2R.mu. protein.
Career Highlights
Takeshi Doi is currently engaged with Boehringer Ingelheim International GmbH, where he applies his expertise in biotechnology and protein engineering. His career highlights reflect a commitment to innovation and a passion for transforming scientific research into practical medical solutions.
Collaborations
Throughout his career, Doi has collaborated with renowned colleagues such as Tadatsugu Taniguchi and Masanori Hatakeyama. These partnerships emphasize the importance of teamwork in advancing research and developing new technologies that can significantly impact patient care.
Conclusion
In summary, Takeshi Doi stands out as a vital contributor to biopharmaceutical innovation. His recent patents on recombinant protein receptors for IL-2 demonstrate his commitment to improving therapeutic options for various medical conditions. As he continues his work at Boehringer Ingelheim, the future holds promising advancements rooted in his innovative spirit.